HAEMATO AG successfully completes capital increase
HAEMATO AG (ISIN: DE000A289VV1, WKN: A289VV) has successfully completed the capital increase which was announced on March 24, 2021. The capital increase was oversubscribed. The Company increased its share capital by € 475,391.00 to € 5,229,307.00 by issuing a total of...
HAEMATO AG plans cash capital increase to finance private label business
HAEMATO AG plans cash capital increase to finance private label businessHAEMATO AG resolves to carry out a cash capital increase using the Authorized Capital 2018 with exclusion of subscription rights in the amount of up to 10% of the share capital to finance the...
HAEMATO PHARM GmbH as a subsidiary of HAEMATO AG receives a special approval according to § 11 Abs. 1 MPG
Ad hoc of HAEMATO AG:HAEMATO PHARM GmbH as a subsidiary of HAEMATO AG (symbol: HAEK) received a special approval in accordance with § 11 Para. 1 MPG from the Federal Institute for Drugs and Medical Devices ( BfArM) for the antigen rapid test for self-testing by...
Patrick Brenske to be the sole member of the Executive Board of HAEMATO AG in the future
Patrick Brenske, member of the Executive Board of HAEMATO AG since November 30, 2020 and Head of Purchasing and Sales of the HAEMATO Group for approximately eight years until 2015, will lead HAEMATO AG as sole member of the Executive Board in the future.
HAEMATO AG acquires “M1 Aesthetics GmbH” from M1 Kliniken AG – Contribution of the company within the scope of a capital increase in kind of HAEMATO AG
Berlin, 15.12.2020 – M1 Kliniken AG and HAEMATO AG today signed a contract for the acqui-sition of all shares in M1 Aesthetics GmbH by HAEMATO AG. M1 Kliniken AG will contribute M1 Aesthetics GmbH to HAEMATO AG within the scope of a capital increase through contri-bution in kind. For this purpose, the Management Board of HAEMATO AG decided today with the approval of the Supervisory Board to increase the company’s share capital by EUR 2,467,201 to EUR 4,753,916 by issuing 2,467,201 new shares of HAEMATO AG through a ca-pital increase against contribution in kind under exclusion of the subscription right of the shareholders by using the existing authorised capital. The new shares will be subscribed and taken over exclusively by M1 Kliniken AG. The transaction will be implemented with effect from 1.1.2021. After completion of the transaction, M1 Kliniken AG will hold a total of 75.8% of the share capital of HAEMATO AG.
HAEMATO AG: Expansion of the board of directors: Strengthening the strategic and operative implementation of the product business in the Haemato Group Schönefeld, 30.11.2020 - The supervisory board of HAEMATO AG has appointed Mr. Patrick Brenske to the board of...
HAEMATO AG
HAEMATO AG
Lilienthalstraße 5c
12529 Schönefeld
Germany
Phone: +49-30 897 30 86 70
Telefax: +49-30 897 30 86 79
E-Mail: info@haemato.ag
HAEMATO Group